Advertisement

  

Certainly Uncertain: Challenges in Communicating HIV Risk

Summer 2012

 < Prev  |  1  |  2 

Explaining How Much a Strategy Can Reduce Risk (Relative-Risk Reduction)

The effectiveness of different HIV prevention strategies and tools can vary greatly. Simply stating that a strategy reduces risk without saying by how much can be misleading. If a person overestimates the effectiveness of a strategy, they could potentially feel a false sense of security and, as a result, engage in more risky behaviours, thus increasing their overall risk of HIV transmission.

How much a strategy reduces risk is most often communicated as a percent change. For example, a recent study known as HPTN 052 found that antiretroviral treatment can reduce the risk of heterosexual HIV transmission by up to 96%.8

Risk reduction can also be communicated in other ways. For example, a 96% relative risk-reduction is equivalent to approximately a 26-fold decrease in risk. Since the percent change is generally a higher value than the fold or times change, communicating risk reduction as a percent may lead a person to overestimate the level of protection provided by a strategy.

Advertisement

It's important for clients to understand that the relative risk reduction associated with a prevention strategy is not a static value, but can change depending on how well the strategy is used. For example, the ability of antiretroviral treatment to reduce the risk of HIV transmission will be much lower than 96% if a person does not adhere to their medications or if one partner has an STI. Similarly, when condoms are used consistently and correctly, they provide close to 100% protection; however, when they are used incorrectly and inconsistently, this level of protection drops.

Furthermore, the relative risk reduction calculated in a study may not apply to everyone. Clinical trials enroll specific populations, so the results may not be directly transferable to other populations. For example, the HPTN 052 study enrolled heterosexual serodiscordant couples almost exclusively and we don't know if the results also apply to gay men and people who use injection drugs.

In addition, trials typically provide a comprehensive package of prevention services to participants -- such as adherence and risk-reduction counselling, free condoms, regular STI testing and STI treatment -- all of which may improve the protection provided by a strategy. In the "real world" outside of a clinical trial, the same prevention strategy may be less effective because the comprehensive package of services is not readily available.


Considering Baseline Risk

Clients not only want to know how much a strategy can reduce their risk, they also want to know their absolute risk of HIV transmission while they are using a strategy.

Relative risk numbers describe changes in risk but do not tell us what the risk is changed to. For example, we know that successful antiretroviral treatment can reduce the risk of heterosexual HIV transmission by up to 96%. This means that the risk has been reduced significantly compared to what it was initially; it does not mean that the risk has been reduced to 4%. In other words, relative risk is a comparison and does not say anything about what the actual risk is.

Consequently, it is difficult for clients to use relative risk information by itself to assess their risk of HIV transmission while using a prevention strategy. Assessing this risk requires that clients also have a good understanding of the context in which they are using the strategy and what their risk was to begin with, also known as their baseline risk.

As a result of differences in baseline risk, it's possible for two people who are using the same risk-reduction strategy in the exact same way to have different absolute risks of HIV transmission. For example, a person who has an STI will have a higher risk of HIV transmission while using a strategy than a person who is using the same strategy and has no STIs.

Simply because a strategy can significantly lower a client's risk does not necessarily mean that their risk while using the strategy will be low. If a person has a very high baseline risk, their risk may still be high after adopting a prevention strategy that significantly reduces their risk. For example, we know that the HIV transmission risk from receptive anal sex is up to 18 times higher per exposure than the risk from vaginal sex.2 Even though a strategy may be able to reduce the risk of HIV transmission by the same amount for both types of sex, the absolute risk may still be higher through anal sex because it poses a higher baseline risk than vaginal sex.

Similarly, a person who is using a certain risk-reduction strategy and is having sex 10 times a week may have a higher risk of HIV transmission than someone who is using the same strategy but is only having the same type of sex twice a week.


Conclusion

Communicating risk can be challenging but a deeper understanding of the concepts explored in this article may help people working in HIV prevention provide a more thorough risk assessment for clients.

Below are some suggestions for assessing and communicating risk.

  • If you use qualitative expressions, such as "high-risk" or "low-risk," be clear about the criteria used to assign an activity to each category.
  • If you provide numbers, make sure you explain what these numbers mean and how they can change as a result of biological risk factors.
  • Be sure to explore the factors that influence a client's risk of transmission from an exposure and over time. Explain that the overall risk of HIV transmission increases with every exposure.
  • When communicating how well a prevention strategy will work for a client, discuss the factors that can make a strategy less effective. Also explore how a client's baseline risk will influence their risk of HIV transmission while using a prevention strategy.
  • Using visual aids and scenarios may help a client understand their risk.
  • In addition to talking about HIV risk in terms of probabilities, you may want to also talk about how transmission occurs and about the epidemiology of HIV in Canada.
  • Since perceived risk is only one factor that influences risk-taking decisions, it is also important to explore the other factors that may be playing a role in a client's decision-making, such as their understanding of HIV and motivations for engaging in unprotected sex.


Resources

Views From the Front Lines: Communicating Risk

Understanding Risk: A Conversation

James Wilton is the project coordinator of the Biomedical Science of HIV Prevention Project at CATIE. James has an undergraduate degree in Microbiology and Immunology from the University of British Columbia.


References

  1. Baggaley RF, White RG, Boily M-C. HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. International Journal of Epidemiology. 2010 Aug;39(4):1048-63.
  2. Boily M-C, Baggaley RF, Wang L et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infectious Diseases. 2009 Feb;9(2):118-29.
  3. Wawer MJ, Gray RH, Sewankambo NK et al. Rates of HIV-1 Transmission per Coital Act, by Stage of HIV-1 Infection, in Rakai, Uganda. Journal of Infectious Diseases. 2005 May 1;191(9):1403-9.
  4. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. Journal of Infectious Diseases. 2008 Sep 1;198(5):687-93.
  5. Ward H, Rönn M. Contribution of sexually transmitted infections to the sexual transmission of HIV. Current Opinion in HIV and AIDS. 2010 Jul;5(4):305-10.
  6. Atashili J, Poole C, Ndumbe PM et al. Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS. 2008 Jul 31;22(12):1493-501.
  7. Cohen CR, Lingappa JR, Baeten JM et al. Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples. PLoS Medicine. 2012 Jun;9(6):e1001251.
  8. Cohen MS, Chen YQ, McCauley M et al. Prevention of HIV-1 infection with early antiretroviral therapy. New England Journal of Medicine. 2011 Aug 11;365(6):493-505.
 < Prev  |  1  |  2 


  

This article was provided by Canadian AIDS Treatment Information Exchange. It is a part of the publication Prevention in Focus: Spotlight on Programming and Research. Visit CATIE's Web site to find out more about their activities, publications and services.
 

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement
Advertisement